BioSpace News Archive

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, July 30, 2020 at 5pm ET to discuss second quarter 2020 financial results and provide a corporate update. The live and replayed webcast of the call will be available through the company’s we

Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the second quarter ended June 30, 2020, after market close on Monday, August 10th at 4:30 pm Eastern time. The company also announced that incoming Chief Executive Officer Kevin Helash, a Canadian citizen, has received his vi

Cradle Genomics today announced the expansion of its executive team with the additions of Tanya Moreno, PhD, as Vice President of Development and Sue Gross, MD, as Chief Medical Officer.

EpimAb Biotherapeutics announced the appointment of Professor Mark Smyth to the company’s Scientific Advisory Board. Currently a Senior Scientist and the Immunology Department Coordinator at QIMR Berghofer Medical Research Institute, Professor Smyth brings over 20 years of immuno-oncology expertise and research experience to the Scientific Advisory Board.

The telehealth market is riding on the wave of growth. This is because telehealth is no longer an option, but a necessity due to the increasing dangers of COVID-19.

Mobile technology has expanded significantly across the globe in recent years.

According to Transparency Market Research’s latest report on the global Implantable Medical Devices market for the historical period 2017–2018 and forecast period 2019–2027.

The healthcare industry has witnessed severe amount of changes with automation paving the way for newer approaches characterized by efficiency.

According to Transparency Market Research’s latest report on the global digital pathology market for the historical period 2017–2018 and forecast period 2019–2027, rising awareness about digital pathology and increase in demand for advanced technology are the factors likely to boost the growth of digital pathology market.

— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —